Колхицин

Quick links

Choose a section

Quick links to important sections

Advertisements

Колхицин

Advertisements
Advertisements

Treatment option: Gout, Fits, Behcet Syndrome

Advertisements

Overview of Колхицин

Quick Facts

Property Description
Active Ingredient Colchicine
Form Tablets (most common), Capsules, Injection solution
Pharmacological Class Antigout Agent
Common Use Management of acute inflammatory episodes
Origin Tropolone Alkaloid (Natural origin, from Colchicum autumnale)

Colchicine: What Kind of Medicine Is It and What Class Does It Belong To?

Colchicine is a prescription-only medication that is specifically classified as an antigout agent (protivopodagricheskoye sredstvo). It is not a broad anti-inflammatory drug or a standard analgesic; its action is highly targeted toward interrupting the cellular processes that cause severe, acute inflammation. The drug is recognized globally by its established international nonproprietary name (INN), Colchicine. Its efficacy in managing acute inflammatory flares is clinically recognized.

Composition and Nature: Colchicine—A Natural Alkaloid in Tablet Form

The active ingredient in this medication is the compound Colchicine (C22H25NO6), making it a single-ingredient product (monopreparat). Colchicine is notable as a powerful tropolone alkaloid derived from the autumn crocus plant (Colchicum autumnale), which defines its unique natural origin. Unlike fully synthetic anti-inflammatory agents, Colchicine's properties stem from this specific, naturally occurring chemical structure.

Colchicine is most commonly available for oral administration in the form of tablets or capsules. The finished product consists of the active substance plus standard pharmaceutical excipients that ensure stability and allow for convenient use.

General Purpose of Colchicine: How Does It Help with Inflammation?

The general purpose of Colchicine is to rapidly control and reduce intense inflammatory episodes driven by excessive white blood cell activity. It achieves this by acting as a tubulin polymerization inhibitor—a unique mechanism that prevents inflammatory cells (like neutrophils) from migrating to the painful area and releasing inflammatory signals. This action targets inflammation at a fundamental cellular level, providing highly targeted relief by interrupting the acute inflammatory cycle—a typical use scenario is managing the sudden onset of a gout flare.

Advertisements

What side effects are possible with Колхицин?

Possible Side Effects and Safety Information

Colchicine has a narrow therapeutic index, meaning there is a small difference between the effective dose and a toxic dose, and it carries a risk of severe or fatal toxicity, particularly in overdose. Early signs of toxicity often include gastrointestinal symptoms.

Common Adverse Reactions (ge 1/100 and < 1/10):

  • Diarrhea (Very common: ge 1/10)
  • Nausea, Vomiting
  • Abdominal pain/cramps

Serious Adverse Reactions and Warnings Treatment must be stopped if signs of toxicity develop (e.g., severe gastrointestinal symptoms) or if symptoms of blood dyscrasias occur (e.g., fever, unusual bleeding, sore throat, or weakness).

  • Blood Dyscrasias: Colchicine can cause potentially life-threatening bone marrow suppression, leading to agranulocytosis, aplastic anemia, leukopenia, and thrombocytopenia (Frequency: Not known/Rare). Monitoring of blood counts may be necessary.
  • Neuromuscular Toxicity: Rhabdomyolysis (muscle breakdown) and myopathy (muscle disease) have been reported, particularly with long-term use or in combination with other myotoxic drugs (e.g., statins, fibrates) or in patients with renal impairment.
  • Fatal Overdose: Cases of fatal overdose have been reported in adults and children. The medication must be kept out of the reach of children.

Population-Specific Safety Considerations

  • Contraindications: Colchicine is contraindicated in patients with severe renal or hepatic impairment, as the body's ability to clear the drug is reduced, significantly increasing the risk of toxicity. It is also contraindicated during pregnancy and breastfeeding.
  • Drug Interactions: Concomitant use with strong or moderate CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine) is strictly contraindicated in patients with renal or hepatic impairment due to a severe and potentially fatal increase in colchicine concentration. Grapefruit juice can also increase plasma concentration and should be avoided.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Colchicine

The official Colchicine toxicity profile is documented as biphasic. The initial phase (typically 2–24 hours post-exposure) manifests with severe gastrointestinal disturbances, including nausea, vomiting, abdominal pain, severe bloody diarrhea, and significant fluid loss. The critical, delayed phase (24–72 hours) often involves life-threatening systemic outcomes, specifically affecting the cardiovascular, respiratory, renal, and hematological systems. These severe manifestations include shock, acute renal failure, Disseminated Intravascular Coagulation (DIC), multi-organ failure, respiratory depression, and cardiovascular collapse.

Fatal overdoses have been reported in adults and children. Regulatory documents mandate that any suspected overdose or presence of toxicity symptoms requires seeking immediate medical attention due to the documented potential for severe and fatal consequences. Management is strictly symptomatic and supportive treatment, as no specific antidote is known. The risk of severe toxicity is explicitly documented as increased in populations with pre-existing renal impairment or hepatic impairment, which defines the need for stringent clinical monitoring. This profile underscores that the primary danger is the delayed, systemic collapse, not just the initial gastrointestinal symptoms.

Advertisements

Therapeutic Uses of Колхицин

The primary therapeutic utility of Colchicine is relevant in contexts involving inflammatory or irritative states. It is commonly used in clinical settings marked by symptoms that become more disruptive during flare-ups and in the long-term management of specific recurrent inflammatory syndromes. Colchicine is classified as an anti-gout agent with therapeutic uses across multiple inflammatory conditions.

The medication is relevant for easing symptoms related to inflammatory or irritative states in conditions such as acute gout flares, Familial Mediterranean Fever (FMF), and pericarditis. It is applied in situations where symptoms create noticeable physiological strain, commonly used when short-term symptomatic assistance is needed. The therapeutic benefit provides support that helps ease the overall symptom burden of symptoms related to physical discomfort, joint swelling, and redness during acute attacks, and assists with maintaining stability when symptoms are more noticeable in recurring conditions.

“The medication is applied to ease symptom burden and may help patients cope more steadily with difficult episodes of associated pain and inflammation.”

Quick Fact: Relief for Acute and Recurrent Inflammation

Property Description
Primary Context Acute, episodes of localized discomfort (e.g., gout)
Secondary Context Long-term symptomatic support for recurrent systemic discomfort (e.g., FMF)
Symptom Focus Symptoms related to physical discomfort, joint swelling, systemic fever, and inflammatory chest discomfort
Patient Benefit Provides supportive relief and assists with maintaining functional stability during flares

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Colchicine is an oral medication with official eligibility rules determined by governmental regulatory bodies. Patients who must not use this medicine are those with a history of hypersensitivity to the drug or any of its ingredients, or those with existing blood dyscrasias (severe blood disorders).

Contraindicated Populations (Prohibited Use)

Population Constraint
Severe Organ Impairment Patients with severe renal impairment (kidney failure) or severe hepatic impairment (liver dysfunction) must not use colchicine due to the high risk of toxic accumulation.
Combined Drug Interaction Use is contraindicated in patients with any degree of renal or hepatic impairment who are concurrently taking a strong CYP3A4 inhibitor or a P-glycoprotein (P-gp) inhibitor (e.g., certain antibiotics or antifungal drugs), as this combination can lead to life-threatening toxicity.
Pregnancy/Lactation Use is generally contraindicated during pregnancy and breastfeeding. Women of childbearing potential are advised to use effective contraception.

Populations Requiring Special Consideration

  • Elderly and Debilitated Patients: Use requires caution and close monitoring due to increased risk of toxicity, even with normal organ function.
  • Mild-to-Moderate Impairment: Patients with mild to moderate renal or hepatic impairment require close monitoring and potential dosage adjustment.
  • Pediatric Use: The medicine is not recommended for the treatment or prevention of gout flares in children. However, it is officially authorized for use in children 4 years of age and older for Familial Mediterranean Fever (FMF).
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Colchicine is primarily cleared from the body through the drug-metabolizing enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Co-administration with inhibitors of these systems can significantly increase colchicine plasma concentrations, leading to the risk of life-threatening toxicity.

Pharmacokinetic Interaction Restrictions

Interacting Substance Type Regulatory Requirement
P-gp and Strong CYP3A4 Inhibitors (e.g., clarithromycin, certain HIV protease inhibitors) Formal Contraindication in patients with renal or hepatic impairment.
Strong or Moderate CYP3A4/P-gp Inhibitors (e.g., ketoconazole, cyclosporine) Requires mandatory dose reduction or temporary interruption of colchicine therapy.

Pharmacodynamic and Substance Interactions

Co-administration with other medicines known to cause muscle damage (myotoxic agents), such as statins (e.g., simvastatin) or fibrates, increases the officially documented risk of neuromuscular toxicity and rhabdomyolysis.

Patients must avoid the consumption of grapefruit or grapefruit juice while taking colchicine, as this substance inhibits both CYP3A4 and P-gp, resulting in higher systemic exposure. The severity of pharmacokinetic interactions is specifically heightened in elderly patients and those with pre-existing renal or hepatic impairment, regardless of the specific combination.

Advertisements

Mechanism of Action

How Colchicine (Колхицин) Works

Colchicine exerts its targeted effect by primarily acting on cellular structure and key inflammatory signaling pathways, modulating excessive, dysregulated physiological signaling.


1. Inhibition of Microtubule Function

This core mechanistic domain involves Colchicine's binding to the tubulin protein, which is essential for assembling microtubules. The disruption of this cellular scaffolding fundamentally impairs the function of highly mobile cells, resulting in a block of downstream cellular processes dependent on microtubule function.


2. Suppression of Neutrophil Activity

This effect is the direct consequence of microtubule inhibition, primarily affecting neutrophils (inflammatory white blood cells). By interfering with the cell's structure, Colchicine suppresses its chemotaxis (movement toward inflammation) and the release of inflammatory contents, resulting in reduced mediator release at the cellular level.


3. Modulation of NLRP3 Inflammasome

Colchicine engages a pathway that modulates the NLRP3 inflammasome, a crucial molecular complex that acts as a master regulator of acute inflammation. By interfering with its assembly or activation, the drug suppresses the initiation and release of pro-inflammatory cytokines, such as Interleukin-1 beta (IL-1beta), which alters the signaling trajectory of highly active inflammatory pathways.

Advertisements

Dosage and Administration Information

How to Use Colchicine: Official Administration Guidelines

Colchicine is administered orally and is available in formulations such as tablets, capsules, and oral solution (e.g., 0.6 mg or 0.5 mg strengths). Official dosing instructions are strictly dependent on the condition being addressed. The medication may be taken without regard to meals.


Standard Dosing and Frequency

Scenario Adult Dosing Regimen Maximum Recommended Dose/Course Frequency/Duration Rules
Acute Gout Flare 1.2 mg (initial dose), followed by 0.6 mg one hour later. 1.8 mg over a 1-hour period. Treatment course should not be repeated no earlier than 3 days (72 hours) later.
Gout Prophylaxis 0.6 mg once or twice daily. 1.2 mg/day. Used long-term, potentially for at least the first six months of uric acid-lowering therapy.
Familial Mediterranean Fever (FMF) 1.2 mg to 2.4 mg daily. 2.4 mg/day. Administered in one or two divided doses; dose adjustments are made in 0.3 mg/day increments.

Use Protocol and Special Populations

Administration Rules:

  • If a flare dose is taken while a patient is on prophylaxis, the patient must wait 12 hours after the acute dose before resuming the regular prophylactic schedule.
  • If using the oral solution, the dose must be measured using an accurate milliliter measuring device.

Dose Adjustment:

  • Patients with severe renal or hepatic impairment require a reduction in the starting dose or frequency. For instance, in severe renal impairment, the starting dose for maintenance may be 0.3 mg/day.
  • For patients on dialysis, the total recommended dose for an acute gout flare is reduced to a single 0.6 mg dose, and the course should not be repeated more than once every two weeks.

These official administration guidelines strictly govern the amount, frequency, and timing of Colchicine intake, defining precise steps for both acute and long-term use scenarios.

Advertisements

Recent Clinical Evidence

Overview of Research Evidence

Gout: Management and Prophylaxis

Research has studied Colchicine for both the management of acute gout episodes and the prophylaxis of recurrent flares. Researchers utilized Randomized Controlled Trials (RCTs) and long-term observational follow-up, monitoring changes in joint pain scores and the frequency of acute flares. Findings describe patterns related to changes in reported joint pain and reduced flare incidence over defined periods. However, the evidence quality varies across studies, as some older trials had methodological limitations, and comparative evidence against other anti-inflammatory approaches remains insufficient.

Familial Mediterranean Fever (FMF)

Controlled studies and long-term observational data have explored the use of Colchicine for Familial Mediterranean Fever. This research included both adults and children, focusing on tracking the frequency and severity of acute FMF attacks. Studies describe patterns observed related to a lower measured frequency of attacks over time. Data for certain groups, such as very young children (under 4 years of age), remain limited, and research is still exploring precise genetic relationships.

Cardiovascular and Pericarditis Evidence

Colchicine was evaluated in large-scale RCTs for the secondary prevention of Major Adverse Cardiovascular Events (MACE) and for acute and recurrent pericarditis. For MACE, data describe patterns related to the measured incidence of events; however, findings were mixed when comparing acute versus chronic coronary syndromes, suggesting inconsistency in outcomes in certain subgroups. For pericarditis, multiple RCTs consistently describe patterns observed related to the measured incidence of recurrence.

Research Gaps and Limitations

While evidence has been collected, long-term effects are not fully established beyond the trial periods, indicating that the maintenance of observed outcomes over a very long span may be uncertain. Data for certain special populations, such as older adults with specific comorbidities, remain insufficient. Comparative evidence against newer approaches in certain chronic inflammatory states is also lacking.

Key Studies & References

  1. Colchicine - StatPearls - NCBI Bookshelf (Review supporting established Gout and FMF indications)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Колхицин (FAQ)

Q: What should I do if I forget to take Colchicine?

Official administration guidelines describe the procedure for a missed dose. The instructions state that a missed dose may be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. If the next dose is due soon, the guidance indicates that the prior dose should be skipped, and the regular schedule should be resumed. Official guidance specifies that two doses should not be taken at the same time.

Q: Can I drink alcohol while taking Colchicine?

Official drug information generally does not list alcohol as a substance that directly interferes with the way the body processes Colchicine. However, for certain conditions like gout, official medical information states that alcohol consumption itself may increase uric acid levels in the blood. This effect may potentially exacerbate the underlying condition for which the medication is prescribed.

Q: Can Colchicine affect my ability to drive or operate machinery?

Official product information and regulatory documents list potential adverse effects that may affect the central nervous system, such as reports of dizziness or feeling fatigued. Because these effects could potentially impair concentration and coordination, the regulatory documentation recommends caution. Patients are advised to know how the medicine affects their personal function before driving or operating heavy machinery.

Q: Can Colchicine affect male fertility?

Official medical information, citing various reports and human studies, indicates that Colchicine may temporarily impair fertility in males. This detail is mentioned in official product information, which indicates that the effect may be transient and, in some cases, reversible after treatment is discontinued. This information is typically found in documentation sections discussing reproductive potential.

Q: What is known about the use of Colchicine for treating COVID-19?

Major regulatory-affiliated medical panels have evaluated the potential role of Colchicine in COVID-19 treatment. The current guidance from these panels indicates against its use for patients who require hospitalization. Furthermore, the official guidance concludes that for non-hospitalized patients, there remains insufficient scientific evidence to establish a recommendation for or against its use as a treatment option.

Advertisements

How should Колхицин be stored and disposed of?

How to Store and Dispose of Colchicine

Official regulatory labeling dictates specific conditions for storing and disposing of Colchicine to ensure product stability and safety.


Storage Requirements

Colchicine must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture and kept in its tight, light-resistant container, which should be tightly closed.

Storage Factor Requirement
Temperature Range 20 C to 25 C (Controlled Room Temp.)
Environmental Protection Protect from light and moisture
Container Rule Must be tight and light-resistant

Child Safety and Disposal

Due to the risk of fatal overdose, it is a mandatory requirement that Colchicine must be stored out of the sight and reach of children. Disposal of unused or expired product must be done according to local requirements and regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Колхицин found in:

A-Z Index: